]>
IRCT20200903048603N1 IRCT 2020-10-04 Shiraz University of Medical Sciences "Effect of Licorice in treatment of Nonalcoholic Fatty Liver Disease" Effects of licorice root on metabolic factors, hepatic enzymes, hepatic steatosis, and oxidative stress in obese women with nonalcoholic fatty liver disease 2019-05-22 anticipated 60 Complete https://irct.ir/trial/50727 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization by computer randomization method using www.randomization.com Double_ blind, Blinding description: Double blind. 3 Nonalcoholic fatty liver disease. Intervention 1: Intervention group: Licorice root powder 1000 mg / day. Intervention 2: Control group: Maltodextrin 1000 mg / day. No - There is not a plan to make this available Justification or reason for not sharing IPD is Nonexistence more information.
public Pouya Rostamizadeh
School of Nutrition and Food Sciences, Razi Blvd, Shiraz, Iran
Shiraz Iran (Islamic Republic of) ۷۱۵۳۶-۷۵۵۴۱ +98 71 3725 1007 Pouyarostamizadeh@gmail.com Shiraz University of Medical Sciences scientific Zohreh Mazloom
School of Nutrition and Food Sciences, Razi Blvd, Shiraz, Iran
Shiraz Iran (Islamic Republic of) ۷۱۵۳۶-۷۵۵۴۱ +98 71 3725 1007 Zohreh.mazloom@gmail.com Shiraz University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Lack of acute or chronic Liver disease Lack of using of Tabacco or alcohol Lack of cardiovascular diseases, and Hypertension Lack of Diabetes Mellitus, Kidney diseases, Malignancy, Viral Hepatitis, Wilson disease Hemochromatosis, Cystic fibrosis and Autoimmune diseases Lack of using of any approved therapies known to have potential benefit in NAFLD control within the previous 3 months Lack of using of Hepatotoxic drugs within the past 6 months 18 years 65 years Female Lack of Fatty Liver in Ultrasonography K76.0 Fatty (change of) liver, not elsewhere classified Treatment - Drugs Placebo Intervention group: Licorice root powder 1000 mg / day Control group: Maltodextrin 1000 mg / day Liver steatosis. Timepoint: Previous of intervention and 3 months after of initiating of study. Method of measurement: Ultrasonography. Malondialdehyde. Timepoint: Previous of intervention and 3 months after of initiating of study. Method of measurement: Analysis of serum samples. Alanine aminotransferase. Timepoint: Previous of intervention and 3 months after initiating study. Method of measurement: Analysis of serum samples. Aspartate aminotransferas. Timepoint: Previous of intervention and 3 months after of initiating study. Method of measurement: Analysis of serum samples. Gama gluthamyl transpeptidase. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis os serum samples. Lipid profile. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples. Fasting blood sugar. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples. Serum insulin. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Analysis of serum samples. HOMA- IR. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: ( serum insulin × Fasting blood sugar) ÷ 405. Wheight. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Using scale (kg). BMI (Body mass index). Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Wheight(kg) ÷ (Height (m) × Height (m) ). Liver steatosis. Timepoint: Previous of intervention and 3 months after initiating of study. Method of measurement: Ultrasonography. Shiraz University of Medical Sciences Approved 2019-06-05 Shiraz university of medical sciences Shiraz Universiry of Medical Siences, Zand Blvd, Shiraz, Iran Shiraz Fars Iran (Islamic Republic of)